> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Agency Defends Generic Drug Oversight
- URL: https://www.fdaweb.com/agency-defends-generic-drug-oversight/
- Published: 2026-06-08T12:00:00.000Z
- Updated: 2026-09-14T13:40:43.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5161269

FDA officials are seeking to bolster confidence in generic medicines, highlighting the agency's oversight of drug manufacturing, inspection programs and post-market surveillance while promoting new efforts to expand domestic pharmaceutical production.

In a joint *FDA Voices* [commentary](https://www.fda.gov/news-events/fda-voices/ensuring-quality-and-access-fdas-approach-generic-drug-oversight?utm%5Fmedium=email&utm%5Fsource=govdelivery), CDER Office of Generic Drugs director Iilun Murphy and CDER Office of Pharmaceutical Quality director Mike Kopcha say generic medicines remain a cornerstone of the U.S. healthcare system, accounting for more than 90% of prescriptions dispensed while representing less than 13% of prescription drug spending. The officials said generic drugs have generated more than $3 trillion in savings over the past decade, helping expand patient access to medicines and improve treatment adherence.

The agency's defense of its generic drug oversight comes amid growing public scrutiny of overseas drug manufacturing, supply chain vulnerabilities and periodic concerns about the quality of some generic medicines. "To receive U.S. approval, generic drugs must meet the same rigorous quality standards as brand drugs," Murphy and Kopcha write, emphasizing that manufacturing facilities are subject to current good manufacturing practice requirements whether they are located in the U.S. or abroad.

The FDA also pointed to recent scientific and regulatory advances that have enabled generic competition for increasingly complex medicines. For example, over the past year, the agency approved the first generic versions of complex inhaled therapies including Flovent and QVAR, as well as the first generic version of the GLP-1 receptor agonist Saxenda.

The agency said it recently updated several product-specific guidances aimed at reducing the need for costly and time-consuming clinical studies for generic inhalation products, a move intended to speed development and lower barriers to market entry.

The FDA officials acknowledge that anecdotal reports and public concerns about generic drug quality can undermine confidence in the products but argued that such accounts often fail to reflect the breadth of the agency's oversight activities.

Their commentary also outlines a multi-layered regulatory framework that includes pre-approval reviews, manufacturing inspections, laboratory testing, adverse-event monitoring and post-market surveillance. They say inspection coverage, which was significantly disrupted during the Covid-19 pandemic, is approaching pre-pandemic levels after the agency expanded the use of remote regulatory assessments, records requests and collaboration with foreign regulatory authorities.

The agency is also increasing unannounced inspections of foreign manufacturing facilities, an initiative designed to address longstanding criticism that overseas drug plants have historically received advance notice of FDA inspections.

The officials additionally highlight programs intended to encourage domestic pharmaceutical production, which has become a growing priority for policymakers concerned about dependence on foreign suppliers for critical medicines. Among those initiatives are FDA's PreCheck Pilot Program, which is designed to facilitate development of new domestic manufacturing facilities, and a new ANDA Prioritization Pilot that accelerates reviews for generic drug companies that both test and manufacture products in the U.S. "The FDA strongly supports efforts to bring pharmaceutical manufacturing back to the United States because domestic manufacturing capacity is essential for supply chain security and resilience," Kopcha says.

The agency also defends its post-market surveillance system, saying it combines inspection findings, adverse-event reports, laboratory testing results, manufacturing data and supply chain information to identify emerging quality concerns. While they say some third-party laboratory testing can play a useful role, they warned that some outside analyses have employed questionable methodologies that produced inaccurate results and unnecessarily alarmed patients. The agency notes that although generic medicines account for roughly 90% of prescriptions dispensed in the United States, they represent only about 40% of product-quality defect reports submitted to FDA.

The officials also point to progress in reducing drug shortages, stating that FDA efforts to expedite reviews of generic applications have contributed to a sharp decline in shortages. According to the agency, only four new drug shortages were reported in 2025, compared with a peak of 251 in 2011.

Looking ahead, Murphy and Kopcha say FDA will continue pursuing evidence-based regulatory policies aimed at maintaining quality standards while improving patient access to affordable medicines.